Although our results were similar to Finn et al’s unpublished data, our data showing that the combination of Ang-2 and FGF19 levels is a more sensitive marker for predicting disease progression in HCC patients being treated with Lenvatinib than the Ang-2 or FGF19 level alone is a novel finding. This evidence concerns the gene ANGPT2 and hepatocellular carcinoma.